(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors

Study ID
NCT02508532

Study type
Interventional

Study phase
Phase 1

Study status
Completed

Trial Acronym

Trial Summary

This is a Phase 1, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antineoplastic activity of avapritinib (formerly BLU-285), administered orally (PO), in adult patients with unresectable GIST or other relapsed or refractory solid tumors. The study consists of 2 parts, a dose-escalation part (Part 1) and an expansion part (Part 2).

More informations

Trial Starting Date

Aug 31,2015

Requirements

Gender All
Minimum age 18 Years
Maximum age N/A

Enrollement Limit

250